Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

09.11.2026

1 Am J Clin Oncol
2 Ann Surg Oncol
1 BMC Cancer
1 Br J Cancer
2 Breast Cancer
1 Breast Cancer (Dove Med Press)
4 Breast Cancer Res
9 Breast Cancer Res Treat
2 Breast J
2 Cancer
1 Cancer Epidemiol Biomarkers Prev
2 Cancer Lett
1 Cancer Res
2 Eur J Cancer
2 Histopathology
1 Int J Cancer
4 J Clin Oncol
2 J Natl Cancer Inst
2 J Surg Oncol
2 Lancet Oncol
2 Oncogene
1 PLoS Genet
2 PLoS One
2 Radiologia (Engl Ed)
1 Radiology


    Am J Clin Oncol

  1. LASPRILLA-PALLARES MA, Garza M, Walker M, Ponce C, et al
    Assessment of Individual and Familial Financial Toxicity Using the Comprehensive Score for Financial Toxicity-Functional Assessment of Chronic Illness Therapy (COST-FACIT): Early Findings From the Navigator-Assisted Hypofractionation (NAVAH) Trial Exp
    Am J Clin Oncol. 2026 Nov 3. doi: 10.1097/COC.0000000000001397.
    >> Share


    Ann Surg Oncol

  2. RAYMOND-KING L, Morton CR, Moses JV, Kaur A, et al
    Psychosocial Outcomes Among Women with Early-stage Breast Cancer Undergoing Mastectomy: A Systematic Review.
    Ann Surg Oncol. 2026 Nov 3. doi: 10.1245/s10434-026-20768.
    >> Share

  3. YANG D, Abdul-Ghani S, Miyagi M, Yamauchi H, et al
    ASO Visual Abstract: Factors Associated with Delays in Breast Cancer Surgery Among Patients from Neighboring Hawaiian Islands Treated on Oahu.
    Ann Surg Oncol. 2026 Nov 2. doi: 10.1245/s10434-026-20845.
    >> Share


    BMC Cancer

  4. AZIZI S, Hosseinpour Z, Akbari A, Akbari ME, et al
    Family history and stage at diagnosis but not prognosis in female breast cancer: a large registry-based cohort study from Iran.
    BMC Cancer. 2026;26:1339.
    >> Share


    Br J Cancer

  5. XIE Y, Wu S, Huang Y, Zhang Y, et al
    On-treatment core needle biopsy identifies early responders for axillary surgery de-escalation: results from a prospective cohort.
    Br J Cancer. 2026;135:1649-1656.
    >> Share


    Breast Cancer

  6. INDRA S
    Methodological considerations in evaluating bioelectrical impedance and quality of life in breast cancer: NACT confounding, generalizability of standing devices, and fluid asymmetries.
    Breast Cancer. 2026 Nov 3. doi: 10.1007/s12282-026-01938.
    >> Share

  7. GAO S, Luo J, Zhang J, Cao G, et al
    Predicting neoadjuvant chemotherapy efficacy in triple-negative breast cancer using DCE-MRI and mammographic texture.
    Breast Cancer. 2026 Nov 4. doi: 10.1007/s12282-026-01932.
    >> Share


    Breast Cancer (Dove Med Press)

  8. HASSAN TM, Alarabi AM, Hussein Eljack RA, Obeid HB, et al
    Sudanese Pharmacists' Knowledge, Attitudes, Practices, and Barriers Regarding Breast Cancer Endocrine Therapy: A Cross- Sectional Survey.
    Breast Cancer (Dove Med Press). 2026;18:641349.
    >> Share


    Breast Cancer Res

  9. ZHU Y, Wang H, Hu Q, Dou Y, et al
    A shapley additive exPlanations (SHAP)-driven quantitative ultrasound radiomics model for non-invasive HER2 status prediction in invasive breast cancer based on intratumoral and peritumoral habitat features.
    Breast Cancer Res. 2026;28:188.
    >> Share

  10. YAMAGUCHI A, Kawanishi K, Ishii K, Fukui Y, et al
    Multicenter development and validation of a serum microRNA-based diagnostic model for breast cancer and its association with tumor burden and biological aggressiveness: an observational case-control study.
    Breast Cancer Res. 2026;28:187.
    >> Share

  11. JIANG C, Bi X, Hua X, Yuan Z, et al
    Time-dependent anti-Mullerian hormone dynamics during GnRHa-based endocrine therapy in young breast cancer survivors: a longitudinal real-world cohort study.
    Breast Cancer Res. 2026;28:185.
    >> Share

  12. RUGO HS, Harbeck N, Hortobagyi GN, O'Shaughnessy J, et al
    Safety and treatment duration of ribociclib + nonsteroidal aromatase inhibitor in HR+/HER2- early breast cancer: a phase 3 randomized controlled trial (NATALEE).
    Breast Cancer Res. 2026;28:186.
    >> Share


    Breast Cancer Res Treat

  13. VALENTIN LOPEZ JC, Ho A, Hughes KS, Bardia A, et al
    Correction to: Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from pathology reports to delineate characteristics of this site of recurrence.
    Breast Cancer Res Treat. 2026;220:23.
    >> Share

  14. HARDEN D, Comander A, Lee H, Stephen NV, et al
    Acceptability of a patient support and educational intervention for black breast cancer survivors.
    Breast Cancer Res Treat. 2026;220:22.
    >> Share

  15. KNOEDLER SA, Fabi A, De Silva P, Sy S, et al
    Venous thromboembolism after breast cancer surgery: incidence, predictive factors and outcomes in 270,564 patients.
    Breast Cancer Res Treat. 2026;220:21.
    >> Share

  16. RAZIS E, Papadopoulou K, Korfiatis N, Christodoulou C, et al
    Brain as a site of first recurrence after adjuvant therapy for early breast cancer: mining the hellenic cooperative oncology group database-The BRACE study.
    Breast Cancer Res Treat. 2026;220:24.
    >> Share

  17. CERQUEIRA PVBD, Campos FAB, Caputo SM, Rouleau E, et al
    Male breast cancer: clinicopathological features and prevalence of germline pathogenic variants.
    Breast Cancer Res Treat. 2026;220:26.
    >> Share

  18. YI B, Kim C, Lee YJ, Lee SB, et al
    Clinicopathological differences between asymptomatic vs symptomatic breast cancer: a 30-year single-center retrospective study.
    Breast Cancer Res Treat. 2026;220:25.
    >> Share

  19. ZEYNOUN J, Evans M, Boldig K, Ali H, et al
    A rare neurological adverse event of palbociclib: a chronic inflammatory demyelinating polyneuropathy (CIDP) mimic.
    Breast Cancer Res Treat. 2026;220:27.
    >> Share

  20. MURPHY CC, Gregory D, Cliff BQ, Betts AC, et al
    Co-payments and adherence to endocrine therapy among Medicaid beneficiaries with breast cancer.
    Breast Cancer Res Treat. 2026;220:29.
    >> Share

  21. SVENDSEN K, Nes LS, Leithe S, Meland A, et al
    Effects of digital stress-management interventions in breast cancer patients 18 months after intervention access.
    Breast Cancer Res Treat. 2026;220:28.
    >> Share


    Breast J

  22. NIU Q, Sun T, Li M, Du L, et al
    Targeted Ultrasound With Contrast Enhancement for Reassessment of MRI-Detected BI-RADS 4 Nonmass Enhancement: Impact on Biopsy Reduction and DCIS Detection.
    Breast J. 2026;2026:e1932231.
    >> Share

  23. DING R, Jia H
    Burden and Projections of Premenopausal and Postmenopausal Breast Cancer Worldwide: A Comprehensive Analysis of GLOBOCAN 2022 Data.
    Breast J. 2026;2026:1290471.
    >> Share


    Cancer

  24. HSU LF, Eisen A, Poll A, Lim DW, et al
    Decision regret following rapid genetic testing at the time of breast cancer diagnosis.
    Cancer. 2026;132:e70663.
    >> Share

  25. LAWRENCE L
    Novel therapies create potential new options for patients with advanced breast cancer: First-line sacituzumab govitecan plus pembrolizumab may improve long-term outcomes for patients with advanced triple-negative breast cancer, whereas the new CDK4/6
    Cancer. 2026;132:e70619.
    >> Share


    Cancer Epidemiol Biomarkers Prev

  26. BOYLE J, Jones RR, White AJ, Zhang JJ, et al
    Creating outdoor air pollution exposome metrics for assessing breast and lung cancer risks in the United States.
    Cancer Epidemiol Biomarkers Prev. 2026 Sep 1. doi: 10.1158/1055-9965.EPI-26-0493
    >> Share


    Cancer Lett

  27. HAO S, Wang X, Ma LX, He M, et al
    Event-free survival in patients with early triple-negative breast cancer receiving platinum-free, de-escalated anti-PD-1 neoadjuvant therapy: an updated analysis of the NeoTENNIS trial.
    Cancer Lett. 2026 Nov 4:218953. doi: 10.1016/j.canlet.2026.218953.
    >> Share

  28. DONG S, Huang R, Wang S, Pan R, et al
    SAGE1-Mediated H3K27ac Enrichment Promotes Chromatin Opening and Fanconi Anemia Repair to Induce Carboplatin Resistance in Triple-Negative Breast Cancer.
    Cancer Lett. 2026 Nov 5:218955. doi: 10.1016/j.canlet.2026.218955.
    >> Share


    Cancer Res

  29. LUNA A, Wang H, Wang L, Dereli Z, et al
    Co-targeting PARP and SHP2 Overcomes Resistance to Apoptosis and Induces Durable Responses in Breast Cancer.
    Cancer Res. 2026 Nov 3. doi: 10.1158/0008-5472.CAN-25-0799.
    >> Share


    Eur J Cancer

  30. DI MICCO R, Corona SP, Bagnardi V, Riccardi S, et al
    From staging to changing strategy: [(18)F]FDG PET/MRI's impact on treatment planning in early breast cancer.
    Eur J Cancer. 2026;249:117809.
    >> Share

  31. DE NONNEVILLE A, Lerebours F, Zemmour C, Dalenc F, et al
    PELICAN-IPC 2015-016/Oncodistinct-003: A randomized non-comparative phase II study of pembrolizumab in combination with neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer.
    Eur J Cancer. 2026;249:117816.
    >> Share


    Histopathology

  32. STEVANOVIC M, Rakha E, Ellis IO, Maccio U, et al
    Long-term outcome of high-grade encapsulated papillary carcinoma of the breast: implications for staging and management.
    Histopathology. 2026;89:941-953.
    >> Share

  33. HARA Y, Yamaguchi R, Oshi M, Otsubo R, et al
    Molecular dichotomy of mucinous carcinoma defined by the presence of solid papillary carcinoma components: an integrative transcriptomic analysis.
    Histopathology. 2026;89:999-1010.
    >> Share


    Int J Cancer

  34. JATOI I, Filho AM, Gierach G, Sung H, et al
    Is Ductal Carcinoma In Situ a Precursor or Low-Risk Variant of Invasive Breast Cancer? A Population Perspective.
    Int J Cancer. 2026 Oct 30. doi: 10.1002/ijc.70799.
    >> Share


    J Clin Oncol

  35. NASH AL, Li Y, Thomas SM, Chiba A, et al
    Patient-Level Evaluation of Optimal Margin Width for Lumpectomy in Ductal Carcinoma In Situ: An Analysis of Patients in the National Cancer Database Special Study.
    J Clin Oncol. 2026;44:3139-3150.
    >> Share

  36. POPPE MM, Le-Rademacher JJ, Haffty BG, Hansen EK, et al
    Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505).
    J Clin Oncol. 2026;44:3128-3138.
    >> Share

  37. CHANG CJ, Pullella K, Keil AP, Mullins CE, et al
    Per- and Polyfluoroalkyl Substance Exposure and Breast Cancer Incidence in the Sister Study.
    J Clin Oncol. 2026 Nov 5:JCO2600318. doi: 10.1200/JCO-26-00318.
    >> Share

  38. SETIAWAN VW
    Perfluoroalkyl Substances and Estrogen Receptor?Negative Breast Cancer: Looking Beyond Traditional Risk Factors.
    J Clin Oncol. 2026 Nov 5:JCO2602225. doi: 10.1200/JCO-26-02225.
    >> Share


    J Natl Cancer Inst

  39. JIANG S, Bennett DL, Rosner B, Colditz GA, et al
    Translating absolute risk of breast cancer into screening frequency: a framework to guide practice.
    J Natl Cancer Inst. 2026 Nov 3:djag411. doi: 10.1093.
    >> Share

  40. HUANG X, Li Y, Sarkar S, Acharya S, et al
    Modeling neoadjuvant treatment plus additional therapy effects on US population breast cancer mortality.
    J Natl Cancer Inst. 2026 Nov 4:djag413. doi: 10.1093.
    >> Share


    J Surg Oncol

  41. DONG G, Heisler A, Namazian S, Wareham C, et al
    Comparing Breast Aesthetics Using a Novel Validated Breast Aesthetic Scale: Standard Breast-Conserving Surgery Versus Oncoplastic Techniques.
    J Surg Oncol. 2026;134:895-903.
    >> Share

  42. NUNES-REIS AR, Paulinelli RR, Rahal RMS, Ribeiro LFJ, et al
    Oncoplastic Surgery Versus Total Breast Reconstruction in Locally Advanced and Multicentric Carcinomas. A Matched Comparative Cohort Study of Oncologic and Aesthetic Outcomes.
    J Surg Oncol. 2026;134:958-967.
    >> Share


    Lancet Oncol

  43. ZHANG J, Shi Y, Zhang Q, Du Y, et al
    Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b/2 trial.
    Lancet Oncol. 2026 Nov 5:S1470-2045(26)00378.
    >> Share

  44. VALENZA C, Tolaney SM
    Co-targeting angiogenesis and immune checkpoints in breast cancer.
    Lancet Oncol. 2026 Nov 5:S1470-2045(26)00526.
    >> Share


    Oncogene

  45. RINKENBAUGH AL, Echeverria GV, Shao J, Qi Y, et al
    Early temporal transcriptional and cytokine responses distinguish chemotherapy sensitivity in patient-derived xenograft models of triple-negative breast cancer.
    Oncogene. 2026 Nov 2. doi: 10.1038/s41388-026-04041.
    >> Share

  46. WANG D, Niu X, Tian J, Liu R, et al
    RHBDL2 promotes cancer stemness and chemoresistance in triple-negative breast cancer through EGFR/PI3K/AKT/mTOR/c-Myc pathway.
    Oncogene. 2026 Nov 5. doi: 10.1038/s41388-026-04007.
    >> Share


    PLoS Genet

  47. MANIRAKIZA AVC, Baichoo S, Uwineza A, Dukundane D, et al
    A common pathogenic founder variant in Rwandan breast cancer cases.
    PLoS Genet. 2026;22:e1012180.
    >> Share


    PLoS One

  48. WANG T, Wu X
    A pretreatment ECM-high/immune-low transcriptomic score is associated with pathological complete response after neoadjuvant therapy in breast cancer.
    PLoS One. 2026;21:e0357532.
    >> Share


  49. Editorial Note: Sclerotium rolfsii Lectin Induces Stronger Inhibition of Proliferation in Human Breast Cancer Cells than Normal Human Mammary Epithelial Cells by Induction of Cell Apoptosis.
    PLoS One. 2026;21:e0361930.
    >> Share


    Radiologia (Engl Ed)

  50. ARENAS RIVERA EN, Grana Lopez L, Presa Abos T, Alvarez Benito M, et al
    BI-RADS(R) v2025 update: Key changes in the breast imaging lexicon.
    Radiologia (Engl Ed). 2026;68:501863.
    >> Share

  51. VILA-TRIAS JOVER E, Alcantara Souza R, Moncusi Armengol A, Vernet Tomas MM, et al
    Diagnostic value of contrast-enhanced mammography versus magnetic resonance imaging in invasive lobular carcinomas: Correlation with pathological assessment and detection of additional lesions.
    Radiologia (Engl Ed). 2026;68:501753.
    >> Share


    Radiology

  52. GARDFJELL A, Ryden L, Nimeus E, Zackrisson S, et al
    Added Value of Preoperative Contrast Enhanced Mammography in Staging of Malignant Breast Lesions (PROCEM): A Randomized Controlled Trial.
    Radiology. 2026;321:e260857.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016